Effects of Blood Pressure Control on Progressive Renal Disease in Blacks and Whites

Hypertension

Volumn 30, Issue 3, 1997, Pages 428-435

  Hebert, Lee A ^a   Kusek, John W ^a   Greene, Tom ^a   Agodoa, Lawrence Y ^a   Jones, Camille A ^a   Levey, Andrew S ^a   Breyer, Julia A ^a   Faubert, Pierre ^a   Rolin, Henry A ^a   Wang, Shin Ru ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; ETHNIC GROUP; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; MIDDLE AGED; PROTEINURIA;

EID: 9844219732     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.30.3.428     Document Type: Article

References (40)

1. Rettig RA, Levinsky NG, eds. Committee for the Study of the Medicare End-Stage Renal Disease Program, Institute of Medicine. Kidney Failure and the Federal Government. Washington, DC: National Academy Press; 1991.
2. US Renal Data System. USRDS 1995 Annual Data Report. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; April 1995.
3. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13-18.
4. Kusek JW, Agodoa LY, Striker GE, eds. Excerpts from the workshop on the biology of kidney disease and hypertension in blacks. Am J Kidney Dis. 1993;21(suppl 1):1-87.
5. Toto RD, Mitchell HC, Smith RD, Lee H-C, McIntire D, Pettinger WA. 'Strict' blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int. 1995;48:851-859.
6. Modification of Diet in Renal Disease Study Group (Beck GJ, Berg RL, Coggins CH, Gassman JJ, Hunsicker LG, Williams GW, writing group). Design and statistical issues of the Modification of Diet in Renal Disease Study. Control Clin Trials. 1991;12:566-586.
7. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med. 1994;330:877-884.
8. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL, for the Modification of Diet in Renal Disease (MDRD) Study Group. Blood pressure control, proteinuria and the progression of renal disease: The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754-762.
9. Kusek JW, Coyne T, deVelasco A, Drabik M, Finlay A, Gassman J, Kiefer S, Powers S, Steinman T. Recruitment experience in the full-scale phase of the Modification of Diet in Renal Disease Study. Control Clin Trials. 1993;14:538-557.
10. Levey AS, Greene T, Schluchter MD, Cleary PA, Teschan PE, Lorenz RA, Molitch ME, Mitch WE, Siebert C, Hall PM, Steffes MW, for the MDRD Study Group and the DCCT Research Group. GFR measurements in clinical trials. J Am Soc Nephrol. 1993;4:1159-1171.
11. 99m Tc-DTPA to inulin. Am J Kidney Dis. 1990;16:224-235.
12. Modification of Diet in Renal Disease Study Group (Greene T, Bourgoignie JJ, Habwe V, Kusek JW, Snetselaar LG, Soucie JM, Yamamoto ME, writing group). Baseline characteristics in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol. 1993;4:1221-1236.
13. Levey AS, Adler S, Caggiula AW, England BK, Greene T, Hunsicker LG, Kusek JW, Rogers NL, Teschan PE, for the MDRD Study Group. Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study. Am J Kidney Dis. 1996;27:652-663.
14. Modification of Diet in Renal Disease Study Group (Levey AS, Adler S, Caggiula AW, England BK, Greene T, Hunsicker LG, Kusek JW, Rogers NL, Teschan PE, writing group). Effects of dietary protein restriction on the progression of moderate renal disease in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol. 1996;7:2616-2626.
15. Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, Paranandi L, Peterson JC, Porush JG, Rauch S, Soucie JM, Stollar C, for the Modification of Diet in Renal Disease Study Group. Achievement and safety of a low blood pressure goal in chronic renal disease. Hypertension. 1997;29:641-650.
16. Maroni BJ, Steinman TI, Mitch WE. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int. 1985;27:58-65.
17. The 1988 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. 1988 Joint National Committee. Arch Intern Med. 1988;148:1023-1038.
18. Paranandi L, Wang S, Greene T, Gassman JJ, Beck GJ, Lazarus JM, and the Modification of Diet in Renal Disease Study Group. Considerations regarding 'measurement visits' during follow-up of clinical trials. Control Clin Trials. 1995;16:120S-121S. Abstract.
19. Modification of Diet in Renal Disease Study Group (Hunsicker L, Adler S, Caggiula A, England B, Greene T, Kusek J, Rogers N, Teschan P, writing group). Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997;51:1908-1919.
20. Whelton PK, Klag MJ. Hypertension as a risk factor for renal disease: review of clinical and epidemiological evidence. Hypertension. 1989;13(suppl I):I-19-I-27.
21. Drizd T, Dannenberg AL, Engel A, for the National Center for Health Statistics. Blood pressure levels in persons 18-74 years of age in 1976-1980, and trends in blood pressure from 1960-1980 in the United States. Vital and Health Statistics. Series 11, No. 234. DHHS Pub. No. (PHS) 86-1684. Public Health Service, Washington, DC. US Government Printing Office. 1986.
22. Whittle JC, Whelton PK, Seidler AJ, Klag MJ. Does racial variation in risk factors explain black-white differences in the incidence of hypertensive end-stage renal disease? Arch Intern Med. 1991;151:1359-1364.
23. McLellan W, Tuttle E, Issa A. Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension. Am J Kidney Dis. 1988;12:285-290.
24. Tierney WM, McDonald CJ, Luft FC. Renal disease in hypertensive adults: effect of race and Type II diabetes mellitus. Am J Kidney Dis. 1989;13:485-493.
25. Brazy PC, Fitzwilliam JF. Progressive renal disease: role of race and antihypertensive medications. Kidney Int. 1990;37:1113-1119.
26. Rosansky SJ, Hoover DR, King L, Gibson J. The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. Arch Intern Med. 1990;150:2073-2076.
27. Rostand SG, Brown G, Kirk K, Rutsky EA, Dustan H. Renal insufficiency in treated essential hypertension. N Engl J Med. 1989;320:684-688.
28. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA, on behalf of the Hypertension Detection and Follow-up Program Cooperative Group. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Hypertension. 1989;13(suppl I):I-80-I-93.
29. Walker WG, Neaton JD, Cutler JA, Neuwith R, Cohen JD, for the MRFIT Group. Renal function change in hypertensive members of the Multiple Intervention Risk Factor Trial: racial and treatment effects. JAMA. 1992;268:3085-3091.
30. Connett JE, Stamler J. Responses of black and white males to the special intervention program of the Multiple Risk Factor Intervention Trial. Am Heart J. 1984;108:839-849.
31. Shulman N, Cutter G, Daugherty R, Sexton M, Pauk G, Taylor MJ, Tyler M. Correlates of attendance and compliance in the Hypertension Detection and Follow-up Program. Control Clin Trials. 1982;3:13-27.
32. Luke RG. Can we prevent end-stage renal disease due to hypertension or to diabetes mellitus? JAMA. 1992;268:3119-3120. Editorial.
33. Spilker B, Cramer JA. Patient Recruitment in Clinical Trials. New York, NY: Raven Press; 1991.
34. Fletcher AE, Bulpitt CJ. How far should blood pressure be lowered? N Engl J Med. 1992;326:251-254.
35. Modification of Diet in Renal Disease Study Group (Levey AS, Beck GJ, Bosch JP, Caggiula AW, Greene T, Hunsicker LG, Klahr S, writing group). Short-term effects of protein intake, blood pressure, and antihypertensive therapy on glomerular filtration rate in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol. 1996;7:2097-2109.
36. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med. 1992;116:78-84.
37. Fumo MT, Teeger S, Lang RM, Bednarz J, Sareli P, Murphy MB. Diurnal blood pressure variation and cardiac mass in American blacks and whites and South African Blacks. Am J Hypertens. 1992;5:111-116.
38. Harshfield GA, Alpert BS, Pulliam DA, Willey ES, Somes GW, Stapleton FB. Sodium excretion and racial differences in ambulatory blood pressure patterns. Hypertension. 1991;18:813-818.
39. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group Report on Primary Prevention of Hypertension. Arch Intern Med. 1993;153:186-208.
40. Wright JT, Kusek JW, Toto RD, Lee JY, Agodoa LY, Randall OS, Kirk KA, Glassock R. Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials. 1996;16:3S-16S.